Importantly, we did not observe a negative impact on other clinical measures (e.g., EDSS, MSFC, Mood 24/7) which could have occurred despite T3’s putative mechanism of action in MS as was seen in prior clinical trials using cytokine modulators, Lenercept and Infliximab, and a peptide analog of human myelin basic protein, Tiplimotide [28]. This evidence concerns the gene MBP and myeloid sarcoma.